Colleen Silk: Fueling Innovation in Rare Bleeding Disorders at THSNA 2026
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”This weekend I attended the 2026 Thrombosis and Hemostasis Summit of North America alongside many dedicated colleagues from our Rare Disease team.
I left feeling inspired by the collaboration and expertise that went into making this meeting such a valuable experience.
It was energizing to connect with the thrombosis and hemostasis community, sharing scientific perspectives and how we’re working to shape the future of care for people living with hemophilia.
From scientific presentations to educational symposia, our presence reflected a continued focus on innovation and progress for the rare bleeding disorders community.
THSNA reinforced the power of fueling conversations, sharing insights, and learning together matters as we work to accelerate progress in this area of unmet need.”
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis
-
Jun 23, 2026, 22:32How WFH Impacted the Bleeding Disorders Community in 2025
-
Jun 23, 2026, 22:03Erin VanDyke: A Journey Through VTE Leadership and Healthcare Transformation